The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data

Sarah R Dawson, Christian D Mallen, Matthew B Gouldstone, Robert Yarham, Gemma Mansell, Sarah R Dawson, Christian D Mallen, Matthew B Gouldstone, Robert Yarham, Gemma Mansell

Abstract

Background: Comorbid mental health problems have been shown to have an adverse effect on the quality of life of people with common eye disorders. This study aims to assess whether symptoms of anxiety and/or depression are more prevalent in people with age-related macular degeneration (AMD) than in people without this condition.

Methods: A systematic search of electronic databases (Medline, CINAHL, EMBASE, PsycINFO) from inception to February 2012 was conducted to identify studies of AMD populations which measured symptoms of anxiety and/or depression. Reference checking of relevant articles was also performed. Data on the study setting, prevalence and how anxiety and depression were measured were extracted from the papers. Critical appraisal was performed using the Critical Appraisal Skills Programme (CASP) tools.

Results: A total of 16 papers were included in the review, from an original search result of 597. The prevalence estimates, taken from nine cross-sectional and cohort studies, ranged from 15.7%-44% for depressive symptoms and 9.6%-30.1% for anxiety symptoms in people with AMD. The seven case-control studies found that people with AMD were more likely to experience symptoms of depression compared with those without AMD, but not more likely to experience symptoms of anxiety.

Conclusions: Overall, the evidence suggests that symptoms of depression are more prevalent amongst AMD populations than anxiety symptoms. The heterogeneity of the studies included in this review means that it is difficult to draw strong conclusions as to the true estimates of depression and anxiety symptoms in AMD populations and prevented formal meta-analysis. Further research which specifies clinical anxiety and gives clear definitions as to the type of AMD being investigated is required.

Figures

Figure 1
Figure 1
Flowchart for how articles were chosen for inclusion.

References

    1. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ. 2003;326:485–488.
    1. Colquitt J. Pegaptanib and Ranibizumab: Final Protocol. 2006. [Accessed 01.02.2009]. [ ]
    1. Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol. 2007;42(6):836–843.
    1. Keller BK, Morton JL, Thomas VS, Potter JF. The effect of visual and hearing impairments on functional status. J Am Geriatr Soc. 1999;47:1319–1325.
    1. Rovner BW, Zisselman P, Schmuely Y. Depression and disability in elderly persons with impaired vision: a follow up study. J Am Geriat Soc. 1996;44:181–184.
    1. Bowler GS, Fayers T, Gouws P. 5.7 times more expensive than liquid gold. Br J Ophthalmol. 2011;95:308–317.
    1. Godlee F. Avastin versus Lucentis. BMJ. 2012;344:e3162.
    1. Mental Health Foundation. Mental health statistics: The most common mental health problems. [Accessed 14.03.2014]. [ ]
    1. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, Bellón-Saameño JA, Moreno B, Švab I, Rotar D, Rifel J, Maaroos H-I, Aluoja A, Kalda R, Neeleman J, Geerlings MI, Xavier M, de Almeida Caldas M, Correa B, Torres-Gonzalez F. Prevalence of common mental disorders in general practice attendees across Europe. Br J Psychiatry. 2008;192:362–367.
    1. Sareen J, Jacobi F, Cox BJ, Belik S-L, Clara I, Stein MB. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006;166(19):2109–2116.
    1. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJG, Goodwin RD, Kubzansky L, Lydiard RB, Massie MJ, Katon W, Laden SK, Stein MB. Anxiety disorders and comorbid mental illness. Gen Hosp Psychiatry. 2008;30:208–225.
    1. Brenes GA. Anxiety, depression, and quality of life in primary care patients. Prim Care Companion J Clin Psychiatry. 2007;9(6):437–443.
    1. Rovner BW, Casten RJ. Neuroticism predicts depression and disability in age-related macular degeneration. J Am Geriatr Soc. 2001;49(8):1097–1100.
    1. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120(8):1041–1044.
    1. Casten RJ, Rovner BW, Edmonds SE. The impact of depression in older adults with age-related macular degeneration. J Vis Impair Blind. 2002;96:399–406.
    1. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.
    1. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol. 2005;50(3):263–273.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med. 2009;151(4):264–269.
    1. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monés J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care resource utilization in neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125(9):1249–1254.
    1. Lotery A, Xu X, Zlateva G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007;91:1303–1307.
    1. Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin. 2008;24(7):2103–2111.
    1. Casten R, Rovner BW, Leiby BE, Tasman W. Depression despite anti-vascular endothelial growth factor treatment of age-related macular degeneration. Arch Ophthalmol. 2010;128:506–508.
    1. Mathew RS, Delbaere K, Lord SR, Beaumont P, Vaegan, Madigan MC. Depressive symptoms and quality of life in people with age-related macular degeneration. Ophthalmic Physiol Opt. 2011;31(4):375–380.
    1. Wysong A, Lee PP, Sloan FA. Longitudinal incidence of adverse outcomes of age-related macular degeneration. Arch Ophthalmol. 2009;127(3):320–327.
    1. Popescu ML, Boisjoly H, Schmaltz H, Kergoat M-J, Rousseau J, Maghadazadeh S, Djafari F, Freeman EE. Explaining the relationship between three eye diseases and depressive symptoms in older adults. Invest Ophthalmol Vis Sci. 2012;53(4):2308–2313.
    1. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108(10):1893–1901.
    1. Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2002;10(3):305–310.
    1. Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K, Berdeaux G. MICMAC Study Group. Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48(4):1498–1503.
    1. Kleinschmidt JJ, Trunnell EP, Reading JC, White GL, Richardson GE, Egbert EM. The role of control in depression, anxiety, and life satisfaction among visually impaired older adults. J Health Educ. 1995;26(1):26–36.
    1. Sun C, Tikellis G, Klein R, Steffens DC, Larsen EKM, Wong TY. Depressive symptoms and age-related macular degeneration in older people: the cardiovascular health study. Ophthalmic Epidemiol. 2007;14(3):127–133.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:261–270.
    1. Radloff LS. The CES-D scale: a self-reported depression scale for research in the general population. Appl Psych Meas. 1977;1:385–401.
    1. Beekman ATF, Deeg DJH, van Limbeek J, Braam AW, de Vries MZ, van Tilburg W. Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in the Netherlands. Psychol Med. 1997;27:231–235.
    1. Yeasavage JA, Brink TL, Rose TL. Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res. 1983;17(1):37–49.
    1. Goldberg D, Bridges K, Duncan-Jones P, Grayson D. Detecting anxiety and depression in general medical settings. BMJ. 1998;297:897–899.
    1. Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431.
    1. Zhang X, Bullard KM, Cotch MF, Wilson R, Rovner BW, McGwin G, Owsley C, Barker L, Crews JE, Saaddine JB. Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005–2008. JAMA Ophthalmol. 2013;131(5):573–581.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅